Difference between revisions of "Melphalan (Alkeran)"

Revision as of 01:14, 27 June 2024

General information

Class/mechanism: Nitrogen mustard, alkylator. Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.^[1]^[2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is established (work in progress)

Peripheral T-cell lymphoma

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

1964-01-17: Initial FDA approval^[5]
Uncertain date: Indicated for the palliative treatment of multiple myeloma. (Based on SWG01)
Uncertain date: Indicated for the palliation of non-resectable epithelial carcinoma of the ovary. (No supporting studies are cited)

History of changes in EMA indication

1963-09-26: EURD

Also known as

Generic names: L-PAM, L-Sacrolysin, L-Sarcolysin, MPL, phenylalanine mustard
Brand names: Alkeran, Alkerana, Evomela, Levofolan, Melfalan, Phelinun

References

[insert-1] 1.0 ^1.1 Melphalan (Alkeran) package insert

[2] Melphalan (Alkeran) package insert (locally hosted backup)

[3] Melphalan (Alkeran) patient drug information (Chemocare)

[4] Melphalan (Alkeran) patient drug information (UpToDate)

[5] Melphalan (Alkeran) FDA approval history

[1]

[2]

[3]

[4]

[5]

@@ Line 4: / Line 4: @@
 <br>Extravasation: [[irritant]] or [[neutral]], depending on reference
-For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 ==Diseases for which it is established ''(work in progress)''==